Ribavirin was reported to work as a cap mimetic [62] and has led to inhibition of eIF4E-mediated progression of acute myeloid leukemia [63], and recently has been touted as effective drug in treatment of Covid-19 in preliminary clinical trials [64, 65]. This evidence concerns the gene EIF4E and acute myeloid leukemia.